Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer
Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer
复制标题
DOI：
10.3892/mco.2013.223
复制
发表时间：
2014-03-01
影响因子：
1.2
通讯作者：
Mizunuma, Hideki
中科院分区：
文献类型：
--
作者：
Yokoyama, Yoshihito;Futagami, Masayuki;Mizunuma, Hideki
上皮性卵巢癌的标准术后化疗是包括铂和紫杉烷的联合治疗。本研究的目的是根据无治疗间期（TFI）和组织学肿瘤类型，研究复发性上皮性卵巢癌患者对铂类药物的敏感程度。回顾性分析了405例诊断为III/IV期卵巢癌的患者的病历，其中包括107例一线治疗获得临床完全缓解后复发的患者。通过比较二线治疗后的无进展生存期（PFS）来评估铂类药物的敏感程度。在复发后接受铂类治疗的浆液性/类腺癌患者中，以下患者组之间的PFS存在显著差异：6个月内复发的患者和6 - 12个月复发的患者; 6 - 12个月复发的患者和12 - 18个月复发的患者;以及那些在12至18个月之间复发的人和那些在18个月后复发的人。相比之下，在复发后接受铂类治疗的透明细胞/粘液腺癌患者中，6个月内复发的患者与6 - 12个月复发的患者之间的PFS无显著差异，而6 - 12个月复发的患者与12个月后复发的患者之间的PFS有显著差异。对于12个月后复发的患者，透明细胞/粘液腺癌患者的PFS显著短于浆液性/粘液样腺癌患者的PFS。因此，我们认为将12个月内复发的透明细胞/粘液腺癌患者归类为铂类耐药，12个月后复发的患者归类为铂类敏感是合理的。
The standard postoperative chemotherapy for epithelial ovarian cancer is a combination therapy including platinum and taxanes. The aim this study was to investigate the degree of platinum sensitivity in patients with relapsed epithelial ovarian cancer according to the treatment-free interval (TFI) and the histological tumor type. The medical records of 405 patients diagnosed with stage III/IV ovarian cancer, including 107 patients who relapsed after attaining a clinical complete response with first-line treatment, were retrospectively reviewed. The degree of platinum sensitivity was assessed by comparing the progression-free survival (PFS) following the second-line treatment. In patients with serous/endometrioid adenocarcinoma who were treated with platinum following relapse, there were significant differences in the PFS between the following groups of patients: those who relapsed within 6 months and those who relapsed between 6 and 12 months; those who relapsed between 6 and 12 months and those who relapsed between 12 and 18 months; and those who relapsed between 12 and 18 months and those who relapsed after 18 months. By contrast, in patients with clear cell/mucinous adenocarcinoma who were treated with platinum following a relapse, there were no significant differences in the PFS between patients who relapsed within 6 months and those who relapsed between 6 and 12 months, while there were significant differences in the PFS between those who relapsed between 6 and 12 months and those who relapsed after 12 months. With regard to the patients who relapsed after 12 months, the PFS of those with clear cell/mucinous adenocarcinoma was significantly shorter compared with the PFS of those with serous/endometrioid adenocarcinoma. Therefore, we considered it justified to classify patients with clear cell/mucinous adenocarcinoma who relapsed within 12 months as platinum-resistant and those who relapsed after 12 months as platinum-sensitive.